INTRODUCTION

Autologous fat grafting (AFG) has long been used as an esthetic technique for correcting volume loss or contour defects. The popularity of AFG increased significantly in the late 1980s, when an abundance of fat from liposuction procedures allowed surgeons to experiment with its therapeutic potential. However, it was not until 2001 that mesenchymal stem/stromal cells—now termed adipose-derived stem cells (ADSCs)—were first isolated from lipoaspirate tissue. Over the past decade, there has been growing interest in the regenerative potential of autologous fat. Adipose-derived stem cells, within the stromal vascular fraction of lipoaspirate samples, demonstrate anti-inflammatory, immunomodulatory, and angiogenic properties. This systematic review aimed to determine the efficacy and safety of autologous fat therapies for wound healing, with an evaluation of the quality of evidence provided by the literature.

Background: There is a growing interest in the regenerative potential of autologous fat. Adipose-derived stem cells, within the stromal vascular fraction of lipoaspirate samples, demonstrate anti-inflammatory, immunomodulatory, and angiogenic properties. This systematic review aimed to determine the efficacy and safety of autologous fat therapies for wound healing, with an evaluation of the quality of evidence provided by the literature.

Methods: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we searched Ovid Medline, Embase, and Cochrane Library databases from inception to November 2018. We included all human studies where wounds were treated with lipotransfer, cell-assisted lipotransfer, stromal vascular fraction products, or isolated adipose-derived stem cells. Study screening and data extraction were performed by 2 authors. The quality of evidence was evaluated using the GRADE approach.

Results: The search strategy returned 5027 citations. From these, 10 observational case series were included in the qualitative synthesis; there were no randomized controlled trials. Patient characteristics, wound etiology, and intervention type differed markedly between studies, precluding formal meta-analysis. Autologous fat grafting was associated with satisfactory wound healing in all studies with low complication rates. However, the quality of evidence was consistently very low.

Conclusions: Autologous fat grafting is an emerging therapeutic option for challenging wounds, although there is insufficient evidence to conclusively demonstrate its effectiveness and adverse event profile. Based on the literature to date, it is unclear whether one type of autologous fat therapy is superior. Well-designed, blinded, prospective randomized controlled trials with adequate methodologic details and objective outcome measure reporting are essential.

PROSPERO ID: CRD42017081499.
to 5000 ADSC precursors per gram of fat.\textsuperscript{2,5} As a result, ADSCs have already been trialed in various regenerative settings, including scar revision and wound healing.\textsuperscript{1,3,8}

However, the literature is confusing when it comes to differentiating between conventional AFG and emerging cell therapy approaches. As such, it is important to clarify what is meant by AFG before elaborating on this review. Here, we define AFG as the transfer of lipoaspirate tissue (lipotransfer) from a donor site to a recipient site. The standard AFG procedure used is the Coleman technique, which may be subdivided into harvesting, refinement, and application steps. Fat harvesting sites are selected according to accessibility or esthetic factors, with studies showing similar outcomes between different donor regions.\textsuperscript{2,10} Small incisions are made, and a blunt-tipped harvesting cannula is advanced into the donor region. Tumescent solution, containing saline with local anesthetic and/or adrenaline, may be infiltrated locally to ease aspiration and minimize bleeding. Harvested lipoaspirate is then typically processed by centrifugation to obtain a condensed adipose tissue pellet, although alternative refinement techniques exist.\textsuperscript{11} The final lipoaspirate product is then injected in layers into the recipient site (Fig. 1).

Although the Coleman technique represents the standard AFG technique, several variations exist. One of these which has gathered considerable attention is cell-assisted lipotransfer (CAL). In CAL, either purified ADSCs or the mixed cellular components of the stromal vascular fraction (SVF) are added to processed lipoaspirate tissue before application. Alternatively, the SVF or isolated ADSCs may be injected without reconstitution; here, the intention is to provide equivalent regenerative effects while limiting the volume of fat injected (Fig. 2).

AFG is an emerging treatment option for cutaneous wounds, with preclinical evidence showing that AFG provides an abundance of cytokines and growth factors that promote soft-tissue regeneration and remodeling.\textsuperscript{1} However, much of the literature supporting AFG for wound healing is based on animal studies, and, as yet, there has been no systematic evaluation of the literature in humans. Therefore, this systematic review aims to critically assess the efficacy and safety of AFG in acute and chronic cutaneous wounds, with an appraisal of the quality of evidence available. A secondary objective is to identify which approach to AFG is superior and whether this varies according to the characteristics of the wound. The protocol for this systematic review was prospectively registered on the International Prospective Register of Systematic Reviews (PROSPERO) (PROSPERO ID: CRD42017081499) and published in full before this review was conducted.\textsuperscript{12}

**METHODS**

This systematic review was conducted in accordance with both the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement\textsuperscript{13} and the Meta-analysis Of Observational Studies in Epidemiology guidelines.\textsuperscript{14}

**Search Methods**

Bibliographic databases (Ovid Medline, Embase, and The Cochrane Library) were searched for relevant articles from inception to November 2018. Free-text terms and MeSH headings were combined with Boolean operators (Table 1).

Database results were merged before discarding duplicate entries. Titles and abstracts were then screened to eliminate unrelated results, and the remaining articles were read in full.

**Study Selection**

All authors agreed on the study selection criteria during the protocol stage (PROSPERO ID: CRD42017081499).\textsuperscript{12} All primary clinical studies using AFG in human subjects
for acute or chronic cutaneous wounds (defined as loss of epithelial continuity) of any depth were included. This included randomized controlled and observational studies with ≥3 participants. There were no restrictions applied to age, sex, defect location, harvesting site, processing technique, application method, or additional adjunct therapies.

Animal studies were excluded, as were those combining AFG with platelet-rich plasma, as this topic has already been reviewed by our research group.\textsuperscript{15} Articles focusing on non-wound etiologies, including esthetic surgery, breast reconstruction, or scar revision, were excluded. The primary search was undertaken in English, and non-English articles not available for translation were excluded.

Table 1. Summary of the Search Terms Used

| Search Terms | MeSH Terms |
|--------------|------------|
| Fat graft*   | Adipose tissue |
| Fat trans*   | Lipectomy |
| Fat transplant* | Skin ulcer |
| Fat inject* | Transplantation, autologous |
| Adipose graft* | Wound healing |
| Adipose stem cell* | |
| Adipose derived stem cell* | |
| Adipose transplant* | |
| ASC* | |
| ADSC* | |
| Lipofill* | |
| Lipotransf* | |
| Lipomodell* | |
| Wound heal* | |
| Wound management | |
| Wound treat* | |
| Ulcer heal* | |
| Ulcer management* | |
| Ulcer treat* | |

Search 1 (fat graft* OR fat trans* OR fat transplant* OR fat inject*) AND (wound heal* OR wound management OR wound treat*)

Search 2 (adipose graft* OR adipose stem cell* OR adipose derived stem cell* OR adipose transplant* OR ASC* OR ADSC*) AND (wound heal* OR wound management OR wound treat*)

Search 3 (Lipofill* OR lipotransf* OR lipomodell*) AND (wound heal* OR wound management OR wound treat*)

Search 4 (fat graft* OR fat trans* OR fat transplant* OR fat inject*) AND (ulcer heal* OR ulcer management OR ulcer treat*)

Search 5 (adipose graft* OR adipose stem cell* OR adipose derived stem cell* OR adipose transplant* OR ASC* OR ADSC*) AND (ulcer heal* OR ulcer management OR ulcer treat*)

Search 6 (Lipofill* OR lipotransf* OR lipomodell*) AND (ulcer heal* OR ulcer management OR ulcer treat*)

ASC, adipose stem cells.
Letters, conference abstracts, and ongoing research were also excluded from the final analysis.

Data Extraction

Data collection and analysis was completed as per the Cochrane Handbook of Systematic Reviews of Interventions.16 All data were recorded (in duplicates) onto apredesigned form by 2 authors to ensure accuracy. Disagreements were resolved by discussion and consensus. Data were collected on the following factors:

1. Study and demographic information
2. Preintervention wound characteristics
3. AFG application methodology
4. Postintervention wound healing outcomes

Where studies provided information from multiple interventions, only data relevant to the current research question were extracted. An additional objective of this systematic review was to assess the quality and details of published articles; therefore, no assumptions were made during data collection, and the authors were not contacted to provide missing information.

Summary Measures

The primary outcome measure specified in our protocol was the proportion of completely healed wounds at 12 weeks. However, owing to study reporting heterogeneity, this was modified to the proportion of completely healed wounds at follow-up times specified by individual authors.

Secondary outcome measures included: the proportion of partially healed wounds at reported endpoints (defined as a 1%–99% reduction in wound surface area); the time to complete wound healing (defined as complete re-epithelialization); and adverse event rates (related to either the donor or recipient site).

Quality of Evidence Appraisal

All authors appraised the quality of evidence across all included studies for each outcome using the systematic approach to rating the certainty of evidence in systematic reviews (GRADE).17

Statistical Analysis

We provide descriptive statistics for all relevant data related to the current research objective. A formal meta-analysis was not performed as a result of marked study heterogeneity. Where possible, summary data are presented as mean and range.

Additional Subgroup Analyses

A secondary aim was to establish if one or more techniques are superior; therefore, data are presented according to the type of intervention used.

RESULTS

Study Selection

The electronic search strategy returned a total of 5027 results. After removing duplicate citations, 4216 titles and abstracts were screened. Thirty-eight articles were read in full to determine their eligibility for inclusion. From this shortlist, 28 articles were excluded due to insufficient number of patients (n = 6), non-wound etiologies (n = 8), non-AFG treatment (n = 8), conference abstracts (n = 5), and unavailable English translation (n = 1). A total of 10 articles were included in the qualitative synthesis (Fig. 3).

Study Characteristics

All 10 included studies were observational case series; there were no randomized controlled trials (RCTs). Studies were undertaken from 2013 onward and across 4 different continents (Table 2).

Wound etiology differed markedly between studies (Table 3). Only 1 study focused on acute wounds.25 Six studies focused on lower limb wounds treated; the remaining studies focused on the face,20,21 upper limb,19,21 and buttocks.20 One study did not describe the location or type of wounds treated.22

Where reported, the average preintervention wound surface area was 21.9 cm² (1.7–247.0 cm²). Five studies did not provide any information on preintervention wound size.19–22,24,25 Eight studies made no assessment of
the wound depth. In the 2 studies that detailed wound depth,18,20 this averaged 0.87 cm (0.2–3.0 cm).

Fat Harvesting

Fat was harvested from the abdomen in the majority of studies with additional sites, including the flank, buttocks, hip, thigh, and calf. Two studies did not specify the donor site.21,26 This procedure, for the majority of cases, was performed under a general anesthetic approach, with only 2 studies using a local anesthetic approach.19,21

The liposuction approach used for harvesting fat was specified or described as a version of the Coleman technique in all studies except for 1 which did not provide this procedural details.26 The majority of studies did not specify whether tumescent solution was administered. Five studies stated that they used tumescent solution, although only 4 provided details as to its constituents. Three of these studies used Klein’s solution,18,20,24 and 1 used adrenaline alone.23

Fat Processing

AFG processing varied considerably between included studies (Table 4). One study involved lipotransfer as per the Coleman technique, without a centrifugation step before administration.23 Five studies used the standard Coleman technique for lipotransfer, centrifuging harvested liposaprate at 3000–3500 rpm for 1–4 minutes.19,20,22,24,27

Two studies used a CAL approach,18,21 one of which used Celution, a commercial system for adipose isolation and processing.21 Two studies used a purified SVF product, isolating the heterogenous cell pellet using an extended centrifugation protocol.25,26 Of the 4 studies using either CAL or SVF-only approaches, only 2 determined cell viability before implantation.21,26 There were no studies using isolated ADSCs only.

Application Method

Seven studies prepared the wound bed before AFG with either debridement or curettage (Table 4). Six studies injected the fat product into the wound edge.18–20,24–26
Two studies injected both the wound edge and the base,\textsuperscript{22,23} and 1 study used microinjections into the wound edge and the base.\textsuperscript{27} One study injected CAL products into the base alone.\textsuperscript{21}

Where reported, the volume of fat injected varied markedly between studies, ranging from 0.5 to 21 mL. Three studies did not report on the volume of lipoaspirate tissue used.\textsuperscript{22,24,25}

Most studies involved a single AFG intervention; only 3 studies used serial AFG treatments following failure to respond in a minority of cases.\textsuperscript{22,23,27} Two studies did not report on the number of AFG applications.\textsuperscript{18,20} All but one study used AFG at the same time of fat harvest,\textsuperscript{18} with the storage of fat between harvest and application not being described. One study did not specify whether AFG was performed at the time of harvesting or as a delayed intervention.\textsuperscript{22}

**Additional Procedures**

One study administered fat into the plane between soleus and gastrocnemius in patients with peripheral vascular disease in an attempt to promote revascularization while concurrently injecting lower limb wounds.\textsuperscript{26}

**Postoperative Care**

Dressing type was reported in only 2 studies, including a hydrobalance biocellulose moist dressing\textsuperscript{19} and negative pressure silicone dressing with topical negative pressure therapy for 4–5 days.\textsuperscript{23} Three studies used concomitant antibiotics in the perioperative period.\textsuperscript{19,23,27} The reasons for this were not detailed in all 3 articles, neither was the exact duration of antibiotic treatment. Immobilization post-AFG was only reported in 1 study, with 4–5 days bed rest.\textsuperscript{23}

Table 3. Summary of Wound Data from Each Study

| Author          | Etiology                                                                 | Wound Type | Location         | Total No. Wounds | No. Patients With Wounds | No. Wounds per Patient | Wound Surface Area (cm\(^2\)) | Wound Depth (cm) |
|-----------------|--------------------------------------------------------------------------|------------|------------------|------------------|--------------------------|------------------------|--------------------------------|------------------|
| Marino et al\textsuperscript{18} | Peripheral vascular disease and diabetes                               | Chronic    | Lower limb       | 10               | 10                       | 1                      | 49.6 (3–247)                  | 0.88 (0.2–3.0)   |
| Del Bene et al\textsuperscript{19} | Digital ulcers in systemic sclerosis                                    | Chronic    | Upper and lower limb | 15               | 9                        | Unspecified             | Unspecified                  | Unspecified     |
| Marangi et al\textsuperscript{20} | Pressure ulcers in paraplegia, spina bifida, multiple sclerosis, cerebrovascular accident, tetraplegia, and diabetes | Chronic    | Ischium and sacrum | Unspecified      | 14                       | Unspecified             | Unspecified                  | 0.86 (0.52–1.13) |
| Del Papa et al\textsuperscript{21} | Digital ulcers in systemic sclerosis                                    | Chronic    | Upper limb       | Unspecified      | 15                       | 15                     | 4.1 (2.4–7.9)                | Unspecified     |
| Piccolo et al\textsuperscript{22} | Burns, trauma, peripheral vascular disease, and diabetes                | Unspecified | Unspecified      | 282              | Unspecified             | 282                    | Unspecified                  | Unspecified     |
| Stasch et al\textsuperscript{23} | Pressure ulcers, peripheral vascular disease, and diabetes             | Chronic    | Lower limb       | 26               | 26                       | 1                      | 5.1 (1.7–10)                 | Unspecified     |
| Caviglia et al\textsuperscript{24} | Cutaneous fistulas in von Willebrand disease and hemophilia A           | Chronic    | Lower limb       | 5                | 5                        | 1                      | Unspecified                  | Unspecified     |
| Kim et al\textsuperscript{25}   | Postfiller necrosis                                                    | Acute      | Face             | 12               | 12                       | 1                      | 18.2 (7.5–35)                | Unspecified     |
| Carstens et al\textsuperscript{26} | Peripheral vascular disease and diabetes                                | Chronic    | Lower limb       | 6                | 6                        | 1                      | 32.4 (13.8–59.4)             | Unspecified     |
| Chopinaud et al\textsuperscript{27} | Hypertensive ulcers                                                    | Chronic    | Lower limb       | 10               | 10                       | 1                      | Unspecified                  | Unspecified     |

**Wound Healing Outcomes**

**Lipotransfer**

The majority of included studies used a lipotransfer technique (Table 3). One study administered unprocessed lipoaspirate without centrifugation.\textsuperscript{26} In this study, 86% of wounds were fully healed and 12% of wounds were partially healed by 4 months. The average time to wound healing was 68 days (40–107), with an average reduction in wound surface area of 90%.

The remaining 5 studies used processed (ie, centrifuged) adipose tissue with follow-up lengths ranging from 3 to 6 months. One study did not report its follow-up duration.\textsuperscript{22} The average number of wounds completely healed at primary follow-up was 65% (40%–100%); however, this was only reported in 3 studies.\textsuperscript{19,24,27} In the 2 studies where partial healing of wounds was reported, this was achieved in 22%\textsuperscript{19} and 60%\textsuperscript{27} of cases. The average reduction in wound area was 85.7% in the only study where this was reported.\textsuperscript{27} The average time to complete wound healing ranged from 4 to 16 weeks in the 2 studies where this was reported.\textsuperscript{24,27}

**Cell-assisted Lipotransfer**

In the 2 studies using a CAL technique, complete wound healing was achieved in 60%\textsuperscript{18} and 100%\textsuperscript{21} of wounds over a follow-up period of 3–6 months. Neither study reported on either partial healing rates or average reduction in wound area. The time to complete wound healing was 3 months\textsuperscript{18} and 1 month.\textsuperscript{21}

**SVF Therapy**

SVF treatment was used in postfiller necrosis and ulcers secondary to peripheral vascular disease and/or diabetes in 2 studies. Rates of complete healing differed markedly between these studies. By 8.5 months, 66% of
Table 4. Summary of the Fat Preparation Methods Used for Each Study

| Components          | Primary Author and Year | Donor Site | Liposuction Technique | Tumescent Solution | Anesthetic | Processing | Cell Viability Checked | Volume Used per Wound (mL) | Application Site | Wound Bed Preparation | No. Applications | Fat Graft in Index Procedure | Dressing | Additional Interventions |
|---------------------|-------------------------|------------|-----------------------|---------------------|------------|------------|------------------------|-----------------------------|-----------------|------------------------|-------------------|--------------------------|----------|---------------------------|
| Lipotransfer (processed) | Del Bene et al.19       | Unspecified | Coleman              | Unspecified         | Local      | Centrifuged for 3 min at 3000 rpm | N/A                      | 2–3 Wound edge          | Debridement     | 1                        | Yes                | Yes                      | Antibiotics |                       |
| Lipotransfer (processed) | Marangi et al.20        | Abdomen, hip, and calf | Coleman | Unspecified         | Unspecified | Centrifuged for 1 min at 3000 rpm | N/A                      | 1 Wound edge            | Unspecified     | Unspecified             | Yes                | Unspecified              | None      |                       |
| Lipotransfer (processed) | Piccolo et al.21        | Abdomen, thigh, and buttocks | Coleman | Unspecified         | Unspecified | Centrifuged for 3 min at 3000 rpm | N/A                      | Unspecified Wound edge and base | Unspecified    | Multiple                | Unspecified      | Unspecified              | Unspecified |                       |
| Lipotransfer (processed) | Caviglia et al.24       | Unspecified | Coleman              | Unspecified         | Local      | Centrifuged for 3 min at 3000 rpm | N/A                      | Wound edge              | Curettage       | 1                        | Yes                | Unspecified              | None      |                       |
| Lipotransfer (processed) | Chopinaud et al.25      | Abdomen, hip | Coleman | Unspecified         | Unspecified | Centrifuged at 2–3000 rpm, time unspecified | N/A                      | 9–21 Wound edge and base | Unspecified | 1                        | Yes                | Unspecified              | None      |                       |
| Lipotransfer (unprocessed) | Stasch et al.23         | Abdomen, thigh | Coleman | Unspecified         | Adrenaline with local anesthetic | Centrifuged for 5 min at 3000 rpm | N/A                      | Wound edge              | Debridement     | Multiple                | Yes                | Yes                      | Antibiotics | topica...pressure dressing for 5 d |
| CAL Mar...18          | Abdomen Coleman         | Adrenaline with local anesthetic | Unspecified | Gelatin extraction centrifuged for 5 min at 3000 rpm | Yes—MTT method | 5 Wound edge | Debridement | Unspecified | No (storage unspecified) | Unspecified | Unspecified              |                       |                       |
| CAL Del Papa et al.21 | Abdomen Coleman         | Unspecified | Local                | Centrifuged for 3 min at 3000 rpm | N/A    | 0.5–1 Wound base | Unspecified | 1 | Yes | Unspecified |                       |                       |
| SVF only Kim et al.25 | Abdomen Coleman         | Unspecified | Unspecified | Centrifuged for 4 min at 3500 rpm | No     | Unspecified Wound edge | Debridement | Multiple       | Yes | Unspecified | Antibiotics (n = 11), composite graft (n = 1), steroids (n = 1), fat injections (n = 2) |                       |                       |
| SVF only Carstens et al.26 | Abdomen, flank          | Unspecified | Unspecified | Disassociated with collagenase for 40 min | Yes—image cytometer | 3–4 Wound edge | Debridement | 1 | Yes | Unspecified | Concomitant administration in plane of gastrocnemius and soleus (n = 6) |                       |                       |

N/A, not applicable; MTT, MTT (3-(4,5-dimethylthiazol-2-yi)-2,5-diphenyltetrazolium bromide, a tetrazole) assay.
Table 5. Summary of the Outcome Measures Reported for Each Study

| Component | Author | Unit of Analysis | Treatment | Follow-up | Time of Primary Outcome (mo) | Frequency of Follow-up | Outcome | Area at Primary Follow-up | Treatment Failures | % of Wounds Healed at Primary Outcome | Area at Total Follow-up | % Wounds Healed (% of Reduction in Wound Area) | Average Time to Wound Healing (wk) | Adverse Events |
|-----------|--------|-----------------|-----------|-----------|-----------------------------|----------------------|---------|------------------------|------------------|----------------------------------|-------------------|------------------------------------------------------------------|------------------------|------------------|
| Lipotransfer (unprocessed) | Del Bene et al. | Per patient | Unspecified | Unspecified | 66 | Unspecified | Unspecified | Lipotransfer | 66 | Unspecified | Unspecified | Unspecified | 60 | 40 | None | None |
| Lipotransfer (unprocessed) | Piccolo et al. | Per ulcer | Unspecified | Unspecified | 2 | Unspecified | Unspecified | Lipotransfer | 60 | Unspecified | Unspecified | Unspecified | 4.2 (2–7) | None |
| Lipotransfer (unprocessed) | Lipotransfer (unprocessed) | Per patient | Unspecified | Unspecified | 2 | Unspecified | Unspecified | Lipotransfer | 60 | Unspecified | Unspecified | Unspecified | 4.2 (2–7) | None |
| Lipotransfer (unprocessed) | CAL Marino et al. | Per ulcer | Unspecified | Unspecified | 2 | Unspecified | Unspecified | Lipotransfer | 60 | Unspecified | Unspecified | Unspecified | 4.2 (2–7) | None |
| Lipotransfer (unprocessed) | CAL Del Papa et al. | Per ulcer | Unspecified | Unspecified | 2 | Unspecified | Unspecified | Lipotransfer | 60 | Unspecified | Unspecified | Unspecified | 4.2 (2–7) | None |
| Lipotransfer (unprocessed) | CAL Stasch et al. | Per ulcer | Unspecified | Unspecified | 2 | Unspecified | Unspecified | Lipotransfer | 60 | Unspecified | Unspecified | Unspecified | 4.2 (2–7) | None |
| CAL | Carstens et al. | Per ulcer | Unspecified | Unspecified | 2 | Unspecified | Unspecified | Lipotransfer | 60 | Unspecified | Unspecified | Unspecified | 4.2 (2–7) | None |
| CAL | CAL Kim et al. | Per ulcer | Unspecified | Unspecified | 2 | Unspecified | Unspecified | Lipotransfer | 60 | Unspecified | Unspecified | Unspecified | 4.2 (2–7) | None |

wounds had completely healed in 1 study. In contrast, no wounds had completely healed by 6 months in the other. Neither study reported a reduction in total wound area or average time to wound healing.

**Adverse Events**

Nine studies reported on whether there were complications related to either the donor or recipient site. In studies using a lipotransfer approach, there was 1 donor site hematoma and 1 patient required additional skin grafting (Table 5).

SVF monotherapies were associated with scarring, erythema, and hypopigmentation in 1 study, although the number of patients affected was not specified. There were no reported treatment-related adverse events in the articles using the CAL approach.

**GRADE Score**

Using the GRADE approach, the quality of evidence for each outcome of interest was assessed as very low. The evidence for AFG in wound healing is based on observational data only with low patient numbers, subjective endpoint evaluation, loss to follow-up, between-study heterogeneity, and unclear effect sizes. This is further confounded by generally poor reporting of methodologic and technical details (Table 6).

**DISCUSSION**

This study represents the first systematic review of AFG for cutaneous wound healing. To date, there have been no RCTs comparing AFG to other wound management options. There is insufficient evidence to demonstrate whether AFG is superior to standard wound care or alternative treatment options. There is also insufficient evidence to establish whether one type of AFG technique leads to superior wound healing and how this varies according to wound etiology.

The rationale for using AFG to enhance wound healing is based on the cellular composition of the SVF. ADSCs within the SVF have been shown to modulate the wound microenvironment by the paracrine secretion of molecules that modify the inflammatory response, activate local stem cell niches, and promote revascularization. The use of either isolated ADSCs or crude SVF is thought to recapitulate the regenerative potential of conventional lipotransfer without the need for large-volume fat injections. This underpins the rationale for CAL—here, the supplementation of harvested liposapitate with either purified ADSCs or the SVF is thought to enhance its regenerative capabilities. However, the absence of comparative RCT-level evidence prevents this review from establishing if CAL is superior to conventional lipotransfer and if ADSC- or SVF-only therapy can reproduce the effects of lipotransfer or CAL techniques in the clinical setting.

It is possible that different cellular components within the SVF act synergistically to enhance wound healing; however, no studies have compared SVF therapy to isolated ADSC therapies. Evidence from a murine myocardial infarction model suggests that they have similar regenerative effects, while a small case series of Crohn’s fistulas...
found that expanded ADSCs were superior to uncultured SVF. Conclusively demonstrating whether ADSCs alone lead to improvements in wound healing when compared with SVF (or vice versa) will be important both for SVF/ADSC monotherapy and for appropriately selecting which cell concentrate should be added to harvested fat for CAL approaches.

Although there is no universally accepted protocol for AFG, various factors related to lipoaspirate harvest, processing, centrifugation, further processing into SVF/ADSC; method of grafting; detailed patient demographics to allow subgroup analysis; and standardized outcome measures (the authors suggest time to wound healing and number of wounds healed to be the most straightforward to measure and clinically applicable).

Although the authors reviewed over 5000 citations and routinely screened the reference lists of all included articles, it remains possible that relevant studies have been missed. In comparison, publication bias represents a more likely source of error. No included studies reported unfavorable results (ie, either AFG improves wound healing or negative results are not reported). A recent systematic review of AFG and ADSC therapy for burn scars illustrates this concern. Based on largely qualitative data from 12 observational human studies, the authors concluded that the early evidence was encouraging; however, the first prospective RCT of AFG for burn scars identified no benefit compared with saline injections.
This review included an intentionally broad range of wound etiologies to establish whether AFG is more effective for particular wound types. For example, the behavior and regenerative potential of ADSCs have been shown to differ in acute and chronic wound microenvironments. However, with insufficient studies for formal subgroup analysis, our narrative synthesis of the literature must be interpreted in the context of a marked between-study heterogeneity. It is also worth highlighting that the variability in outcome measures was used across the literature; broadly, endpoints have been subjectively assessed and do not provide robust quantitative data for a reliable comparative assessment.

**CONCLUSIONS**

This systematic review is the first to look at AFG as a treatment option for cutaneous wound healing. However, due to significant heterogeneity within the existing literature, there is an inability to delineate any superiority of AFG over traditional wound care or treatment options. Nonetheless, in some small, poorly reported studies, AFG has shown encouraging results for cutaneous wounds without unacceptably high complication rates. However, these findings must be interpreted in light of the quality of evidence available, and further larger studies are necessary to determine its efficacy.

Future research should aim to establish how AFG compares with alternative wound management options. Additionally, identifying which AFG technique is superior for wound healing and whether this varies according to wound characteristics will be essential.

There is an urgent requirement for well-designed, blinded, prospective RCTs with adequate methodological details and objective outcome measure reporting. In the first instance, these should use alternative wound management options as a control before comparing different AFG procedures with one another.

**REFERENCES**

1. Condé-Green A, Marano AA, Lee ES, et al. Fat grafting and adipose-derived regenerative cells in burn wound healing and scarring: a systematic review of the literature. *Plast Reconstr Surg*. 2016;137:302–312.

2. Coleman SR. Structural fat grafting: more than a permanent filler. *Plast Reconstr Surg*. 2006;118(suppl):108S–120S.

3. Zuk PA, Zhu M, Mizuno H, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. *Tissue Eng*. 2001;7:211–228.

4. Condé-Green A, Kotamarti V, Marano MA, et al. Adipose stem cells isolated from excised burned tissue: is there potential for clinical use? *Plast Reconstr Surg*. 2016;137:7676–7686.

5. Bellini E, Greco MP, Raposio E. The science behind autologous fat grafting. *Ann Med Surg (Lond)*. 2017;24:65–73.

6. Zuk P. Adipose-derived stem cells in tissue regeneration: a review. *ISRN Stem Cells*. 2013. Available at http://downloads.hindawi.com/archive/2013/719059.pdf. Accessed April 22, 2020.

7. Duscher D, Barrera J, Wong VW, et al. Stem cells in wound healing: the future of regenerative medicine? A mini-review. *Genetherapy*. 2016;62:216–225.

8. Mazzola IC, Cantarella G, Mazzola RF. Management of tracheostomy scar by autologous fat transplantation: a minimally invasive new approach. *J Craniofac Surg*. 2013;24:1361–1364.

9. Negenborn VL, Groen JW, Smit JM, et al. The use of autologous fat grafting for treatment of scar tissue and scar-related conditions: a systematic review. *Plast Reconstr Surg*. 2016;137:31e–43e.

10. Rohrich RJ, Sorokin ES, Brown SA. In search of improved fat transfer viability: a quantitative analysis of the role of centrifugation and harvest site. *Plast Reconstr Surg*. 2004;113:391–395; discussion 396–397.

11. Condé-Green A, Wu I, Graham I, et al. Comparison of 3 techniques of fat grafting and cell-supplemented lipotransfer in athymic rats: a pilot study. *Aesthet Surg J*. 2013;33:715–721.

12. Luck J, Smith OJ, Malik D, et al. Protocol for a systematic review of autologous fat grafting for wound healing. *Syst Rev*. 2018;7:99.

13. Moher D, Liberati A, Tetzlaff J, et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. *PLoS Med*. 2009;7:1–6.

14. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008–2012.

15. Smith OJ, Jell G, Mosabehi A. The use of fat grafting and platelet-rich plasma for wound healing: a review of the current evidence. *Int Wound J*. 2019;16:275–285.

16. Higgins J, Green S. Chapter 22: overview of reviews. *Cochrane Handbook for Systematic Reviews and Meta-Analyses*. 2018;2008:187–235.

17. Guyatt GH, Oxman AD, Vist GE, et al; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*. 2008;336:924–926.

18. Marino G, Moraci M, Armentia E, et al. Therapy with autologous adipose-derived regenerative cells for the care of chronic ulcer of lower limbs in patients with peripheral arterial disease. *J Surg Res*. 2013;185:36–44.

19. Del Bene M, Pozzi MR, Rovati L, et al. Autologous fat grafting for scleroderma-induced digital ulcers. An effective technique in patients with systemic sclerosis. *Handchir Mikrochir Plast Chir*. 2014;46:242–247.

20. Marangi GF, Pallara T, Cagli B, et al. Treatment of early-stage pressure ulcers by using autologous adipose tissue grafts. *Plast Surg Int*. 2014;2014:817283.

21. Del Papa N, Di Luca G, Sambataro D, et al. Regional implantation of autologous adipose tissue-derived cells induces a prompt healing of long-lasting indolent digital ulcers in patients with systemic sclerosis. *Cell Transplant*. 2015;24:2297–2305.

22. Piccolo NS, Piccolo MS, Piccolo MT. Fat grafting for treatment of burns, burn scars, and other difficult wounds. *Clin Plast Surg*. 2015;42:263–283.

23. Stach T, Hoehne J, Huynh T, et al. Débridement and autologous lipotransfer for chronic ulceration of the diabetic foot and lower limb improves wound healing. *Plast Reconstr Surg*. 2015;136:1357–1366.

24. Caviglia H, Landro ME, Gallo E, et al. Is it possible to use autologous adipose graft for wound repair in patients with coagulation disorders? *Haemophilia*. 2016;22:298–302.

25. Kim JH, Park SH, Lee BH, et al. Early intervention with highly condensed adipose-derived stem cells for complicated wounds following filler injections. *Aesthetic Plast Surg*. 2016;40:428–434.
26. Carstens MH, Gómez A, Cortés R, et al. Non-reconstructable peripheral vascular disease of the lower extremity in ten patients treated with adipose-derived stromal vascular fraction cells. Stem Cell Res. 2017;18:14–21.

27. Chopinaud M, Labbé D, Creveuil C, et al. Autologous adipose tissue graft to treat hypertensive leg ulcer: a pilot study. Dermatology. 2017;233:234–241.

28. Zhu M, Zhou Z, Chen Y, et al. Supplementation of fat grafts with adipose-derived regenerative cells improves long-term graft retention. Ann Plast Surg. 2010;64:222–228.

29. Bertozzi N, Simonacci F, Grieco MP, et al. The biological and clinical basis for the use of adipose-derived stem cells in the field of wound healing. Ann Med Surg (Lond). 2017;20:41–48.

30. Howick J, Chalmers I, Glasziou P, et al. The Oxford Levels of Evidence 2. Oxford Centre for Evidence-Based Medicine. 2011 [Cited December 30, 2019]: Available at https://www.cebm.net/index.aspx?o=5653. Accessed April 22, 2020.

31. Yoshimura K, Suga H, Eto H. Adipose-derived stem/progenitor cells: roles in adipose tissue remodeling and potential use for soft tissue augmentation. Regen Med. 2009;4:265–273.

32. Bai X, Yan Y, Song VH, et al. Both cultured and freshly isolated adipose tissue-derived stem cells enhance cardiac function after acute myocardial infarction. Eur Heart J. 2010;31:489–501.

33. García-Olmo D, Herreros D, Pascual M, et al. Treatment of enterocutaneous fistula in Crohn’s disease with adipose-derived stem cells: a comparison of protocols with and without cell expansion. Int J Colorectal Dis. 2009;24:27–30.

34. Keck M, Zeyda M, Gollinger K, et al. Local anesthetics have a major impact on viability of preadipocytes and their differentiation into adipocytes. Plast Reconstr Surg. 2010;126:1500–1505.

35. Hassan WU, Greiser U, Wang W. Role of adipose-derived stem cells in wound healing. Wound Repair Regen. 2014;22:313–325.

36. Raposio E, Simonacci F, Perrotta RE. Adipose-derived stem cells: comparison between two methods of isolation for clinical applications. Ann Med Surg (Lond). 2017;20:87–91.

37. Raposio E, Carnana G, Bonomini S, et al. A novel and effective strategy for the isolation of adipose-derived stem cells: minimally manipulated adipose-derived stem cells for more rapid and safe stem cell therapy. Plast Reconstr Surg. 2014;133:1406–1409.

38. Condé-Green A, de Amorim NF, Pitanguy I. Influence of decantation, washing and centrifugation on adipocyte and mesenchymal stem cell content of aspirated adipose tissue: a comparative study. J Plast Reconstr Aesthet Surg. 2010;63:1375–1381.

39. Hivernaud V, Lefourn B, Robard M, et al. Autologous fat grafting: a comparative study of four current commercial protocols. J Plast Reconstr Aesthet Surg. 2017;70:248–256.

40. Coleman SR. Structural fat grafts: the ideal filler? Clin Plast Surg. 2001;28:111–119.

41. Luck J, Smith OJ, Mosahebi A. A systematic review of autologous platelet-rich plasma and fat graft preparation methods. Plast Reconstr Surg Glob Open. 2017;5:e1596.

42. Gal S, Ramirez JJ, Maguina P. Autologous fat grafting does not improve burn scar appearance: a prospective, randomized, double-blinded, placebo-controlled, pilot study. Burns. 2017;43:486–489.

43. Koenen P, Spanholz TA, Maegle M, et al. Acute and chronic wound fluids inversely influence adipose-derived stem cell function: molecular insights into impaired wound healing. Int Wound J. 2015;12:10–16.